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Abstract: The reduction or cessation of the blood supply to an organ results in tissue ischemia. 
Ischemia can cause significant tissue damage, and is observed as a result of a thrombosis, as 
part of a disease process, and during surgery. However, the restoration of the blood supply often 
causes more damage to the tissue than the ischemic episode itself. Research is therefore focused 
on identifying the cellular pathways involved in the protection of organs from the damage 
incurred by this process of ischemia reperfusion (I/R). The hypoxia-inducible factors (HIFs) are 
a family of heterodimeric transcription factors that are stabilized during ischemia. The genes that 
are expressed downstream of HIF activity enhance oxygen-independent ATP generation, cell 
survival, and angiogenesis, amongst other phenotypes. They are, therefore, important factors 
in the protection of tissues from I/R injury. Interestingly, a number of the mechanisms already 
known to induce organ protection against I/R injury, including preconditioning, postconditioning, 
and activation of signaling pathways such as adenosine receptor signaling, converge on the HIF 
system. This review describes the evidence for HIFs playing a role in I/R protection mediated by 
these factors, highlights areas that require further study, and discuss whether HIFs themselves 
are good therapeutic targets for protecting tissues from I/R injury.
Keywords: hypoxia, adenosine, pre-conditioning, post-conditioning
Introduction
Ischemia, defined as an inadequate blood supply to an organ or part of the body,1 is a 
considerable clinical problem. It is observed in a number of chronic diseases including 
cardiovascular disease and diabetes, acute events such as stroke or myocardial infarc-
tions, and during planned clinical procedures like organ transplantation and general 
surgery. Ischemia leads to a reduction in the supply of nutrients and oxygen as well as 
the removal of waste products from a tissue, and in doing this can lead to irreversible 
tissue damage and death.
Arguably more important is the subsequent reperfusion of the tissue or organ. Upon 
resumption of a normal blood supply, oxygen and nutrients flood back into the tissue. 
This can result in considerable damage to both the tissue in question and, depending 
on the scale of the ischemic insult, the rest of the body. If a severe ischemic episode 
has resulted in extensive necrotic damage, a wave of toxic cellular products can be 
released into the bloodstream upon reperfusion that, in the worst circumstances, can 
result in the death of the patient. However, even in acute ischemic events where this 
does not happen, the rush of nutrients and oxygen into the tissue can cause significant 
tissue damage, mainly through reactive oxygen species (ROS)-mediated oxidative 
damage of proteins, DNA, and lipids throughout the tissue.2,3
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The objective of much research in this area is to find 
means of reducing infarct size and thereby preserving tissue 
function after ischemia–reperfusion (I/R) injury. This has 
involved the investigation of means of inducing a protective 
state in the tissue both before and after the ischemic insult. 
Although studies over many years have demonstrated the 
efficacy of a number of agents in eliciting protection of 
various organs from I/R injury, most often, this demonstra-
tion has not led to the agent becoming an integral part of 
clinical practice. This may well be because we do not yet 
fully understand the intracellular signaling pathways that are 
required to invoke protection and, therefore, cannot design 
agents that can specifically target these pathways without 
off-target effects.
This review will discuss the evidence suggesting that 
the family of hypoxia-inducible factor (HIF) transcription 
factors may well represent such a target. Data from studies 
of methods of protecting tissues from ischemia suggest that 
HIFs may play a central role in mediating cellular  protection. 
Future research strategies to specifically define how HIFs are 
best activated by either preconditioning (PreC) or postcon-
ditioning (PostC) approaches to generate a protected state 
may well lead to novel efficacious therapies to alleviate the 
clinical problems associated with I/R injury.
Control of the HIF  
transcription factors
The HIFs are heterodimeric transcription factors composed 
of an alpha and beta subunit. The beta subunit is considered 
to be constitutively expressed, while the alpha subunit is 
subject to a highly efficient oxygen-dependent system of 
control.4,5 There are three alpha subunits of HIF, of which 
1α and 2α are the best described. Overall regulation of 
expression of the alpha subunits is through oxygen-induced 
proteolytic degradation, which gives a high degree of tem-
poral control over the hypoxic response. Although stable 
under acute hypoxic conditions, alpha subunits are rapidly 
degraded in normoxia through the hydroxylation of target 
prolyl residues (P402 and P564 in human HIF1α) by prolyl 
hydroxylase enzymes (PHD1–3, encoded by the EGLN1-3 
genes).6 These hydroxyprolyl residues are then recognized 
by the von Hippel –Lindau (pVHL) E3 ubiquitin ligase, 
which polyubiquitylates the HIFα subunit, targeting it for 
proteasomal degradation (Figure 1).7 This system provides 
exquisite control over the expression and activity of the 
HIF transcription factors, allowing them to be rapidly and 
reversibly upregulated upon reduction of the environmental 
oxygen.
The PHD enzymes, which represent the oxygen sensors 
in this system, are 2-oxoglutarate-dependent dioxygenases, 
which use 2-oxoglutarate (alpha-ketoglutarate) and oxygen to 
hydroxylate target substrates. They are, therefore, less active 
in low-oxygen (and presumably low-2-oxoglutarate) environ-
ments, such as during ischemia. Although HIF-independent 
roles for the PHD enzymes are becoming clearer, their most 
understood role is through the regulation of the HIF transcrip-
tion factors. PHD2 has been shown as the major hydroxylase 
involved in regulating HIF1α stability,8,9 while PHD1 and 3 
activities have both been correlated with HIF2α stability.10–12 
During ischemic conditions, where PHDs are less active, 
HIFα subunits are rapidly stabilized, leading to the expression 
of the HIF-induced transcriptome.  Interestingly, PHD2 and 
3 are both transcriptional targets of HIF1, providing a HIF1-
specific negative feedback loop (PHD2 and 3 have not been 
shown as HIF2 target genes) where hypoxia-induced HIF1 
activity leads to increased PHD2 and 3 levels and, as a result, 
decreased HIF1α (and potentially HIF2α) expression.13
Importantly, in terms of relevance to I/R injury, condi-
tions that increase ROS generation, such as reoxygenation, 
have been shown to result in a longer-term stabilization of 
HIF1α, thereby inducing a prolonged hypoxic phenotype in 
reperfused cells.14 The mechanism by which this occurs has 
been suggested as the oxidative inactivation of the non-heme 
iron catalytic site of the PHD enzymes,15–17 although a further 
study suggested that the active site of the PHDs may not be 
accessible by ROS.18
Other signaling pathways are also known to increase HIF1α 
protein expression independently of oxygen tension. Activa-
tion of AKT has been shown to increase HIF1α expression in 
normoxic conditions (Figure 1).19 The downstream pathway 
involved in this regulation appears to be through activation 
of mechanistic target of rapamycin ([mTOR] also known as 
FKBP12 rapamycin-associated protein).19 mTOR and mitogen-
activated protein kinases (MAPKs) can both phosphorylate 
4E-BP1 to permit efficient cap-dependent translation of 
HIF1α messenger ribonucleic acid (mRNA).20 In ischemia, 
general translation is shut down through mechanisms including 
nutrient-sensitive inhibition of mTOR to conserve adenosine 
triphosphate (ATP) levels.21 However, cap- independent trans-
lation of some mRNA species, including HIF1 and 2α, is 
conserved.21 As previously mentioned, mTOR acts as a nutrient 
sensor – it is able to sense intracellular concentrations of the 
amino acids leucine and glutamine,22,23 thereby linking nutrient 
availability with anabolic processes. Other metabolic altera-
tions that occur in ischemia are also capable of signaling to 
alter cellular phenotype. Succinate, a tricarboxylic acid cycle 
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metabolite is often found at  considerably higher concentrations 
in ischemic tissue,24,25 and is a well-described inhibitor of the 
PHD enzymes, leading to HIFα stabilization (Figure 1).26
MAPK activity has also been shown to be required for 
the transactivational activity of HIF1 and 2. MAPKs are 
a large family of protein kinases consisting of three main 
groups: extracellular signal-regulated kinases; p38 MAPKs; 
and c-Jun N-terminal kinases.27–29 They are activated in 
response to diverse stimuli including growth factor signaling, 
cellular and environmental stress, and inflammatory cues. 
Once activated, members of this family have been shown to 
phosphorylate HIF1α, leading to enhanced binding of the 
coactivator p300/CBP-binding protein (Figure 1), although 
other independent pathways have also been suggested.30–32
Hence, although oxygen tension is the most potent 
modulator of HIFα stability, there are many diverse means 
of  altering HIF activity that can occur in ischemic and 
 reperfused tissues. Many of these stabilization stimuli are 
downstream of signaling pathways that are known to be 
important in the protection of tissues from I/R injury and, 
therefore, provide some evidence, albeit indirect, for an 
important role for HIF in protection.
The effect of HIF stabilization  
on I/R injury
HIF1α was originally identified as a hypoxia-inducible nuclear 
factor that bound the EPO gene locus and induced its expres-
sion.33 Its gene targets have since been extensively charac-
terized by a number of groups, and the hypoxia responsive 
elements (HREs) to which HIFs bind have been identified in 
numerous gene loci. More recently, it has been suggested that 
HIF1 may also have more wide-ranging effects on the isch-
emic transcriptome through its influence on promoter-bound 
RNA polymerase II, even at loci without associated HREs.34 
HIF2α, also known as endothelial PAS protein 1 was cloned 
in 1997 by a number of groups.35–38 Although its regulation is 
less well-described than that of HIF1a, it also binds to HRE 
sequences and  transactivates its target genes. Although HIF1α 
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Figure 1 The control of HiF expression and activity by factors involved in ischemic signaling.
Notes: HiFα expression is directly regulated by oxygen-dependent PHD enzymes that hydroxylate it in two positions for recognition by the pvHL e3 ubiquitin ligase, which 
targets HiFα for proteasomal degradation. PHD activity can be further controlled by changes in ROS and succinate levels, both of which are increased through mitochondrial 
dysfunction during ischemia. Further regulation of expression is performed through MAPK- and mTOR-mediated control of mRNA translation. Receptor tyrosine kinase 
signaling can increase HiF expression and activity through mTOR and MAPK signaling, while both the adenosine receptors 2A/B and cellular stresses can increase HiF activity 
through MAPK activation. MAPK-mediated phosphorylation of HiF1α is necessary for efficient transactivation of its target genes by enhancing the interaction with p300/CBP.
Abbreviations: α-KG, α-ketoglutarate; A2A/B, adenosine receptors 2A/B; ADORA2A, gene encoding A2A receptor; CD73, the membrane-bound extracellular 
5′-nucleotidase; eTC, electron transport chain; Gs, stimulatory G protein; HiF, hypoxia-inducible factor; MAPK, mitogen-activated protein kinase; mTOR, mechanistic target 
of rapamycin; P, phosphorylated peptide residue; p300/CBP, p300/cyclic AMP adenosine monophosphate; PHD, HiF prolyl hydroxylase enzyme; pvHL, von-Hippel Lindau 
protein; ROS, reactive oxygen species; RTK, receptor tyrosine kinase; TCA, tricarboxylic acid cycle; Ub, ubiquitin; mRNA, messenger RNA.
Hypoxia 2014:2submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
110
Howell and Tennant
is ubiquitously expressed, HIF2α is more limited and has been 
observed in a subset of cell types, including  hepatocytes, 
cardiac myocytes, and endothelial cells.39 The different phe-
notypes observed in the HIF1α−/− and HIF2α−/− mice, as well 
as a number of other studies, strongly suggest that, although 
each shares a set of genes that they regulate, they also each 
control the expression of unique target genes.40–43 Studies 
performed in different cell types have shown that HIF2α 
specifically regulates hypoxic upregulation of gene products 
including cyclin D1, transforming growth factor α, POU5F1, 
and matrix  metalloproteinase 2, whereas HIF1 regulates a 
large number of glycolytic enzymes including glyceraldehyde 
3-phosphate dehydrogenase, phosphoglycerate kinase 1, 
Bnip3, and carbonic anhydrase 9.43–48 Importantly, the precise 
gene set altered by HIF1 and 2 is tissue specific, as it depends 
on the prevailing chromatin structure.49
HIFs are therefore stabilized rapidly upon the loss of 
 oxygen supply, resulting in a concerted transcriptional response 
to modulate cellular phenotype. This transcriptional response 
has wide-ranging effects that are beneficial to  ischemic and 
recently reperfused tissue. As the HIF transcription factors 
regulate the expression of such a considerable number of genes, 
they are likely to exert their protective influence on I/R tissues 
through pleiotropic effects.50 A large number of upregulated 
HIF1 target genes are associated with glycolysis and, therefore, 
permit higher rates of ATP production from glucose, which is 
an oxygen-independent process. This is important both under 
ischemic conditions and upon reperfusion as it allows ATP 
levels to be sustained further into the ischemic episode, as 
well as permitting rapid ATP production after resumption of 
the blood supply. For tissues with considerable ATP demand, 
such as the myocardium, the rapid restoration of ATP genera-
tion capacity is key to retaining function post-I/R. Avoiding 
dependency on oxidative phosphorylation for ATP production 
after reperfusion is important as many mitochondrial metabolic 
enzymes can be inhibited or inactivated by the ROS gener-
ated by reperfusion, and efficient oxidative metabolism may 
therefore have to wait for new protein production by the cell. 
In addition, HIF stabilization also increases the production of 
angiogenic factors by the tissue, such as vascular endothelial 
growth factor, which can aid the restoration of an efficient 
blood supply through the damaged tissue.51
HIFs are a central part of PreC  
and PostC mechanisms
Ischemic PreC (IPC) and ischemic PostC have been shown 
to be effective in reducing infarct size in a number of 
models and tissues.52–57 Both conditioning protocols use 
acute cycles of I/R, with the ischemic episode lasting a 
few minutes.58–61 IPC results in a protected phenotype 
in the tissue that has two phases: one that occurs within 
minutes and can last a few hours, and another that begins 
at around 24–48 hours and lasts a number of days.60,62,63 
There are several lines of evidence that places HIF as a 
central mediator of IPC-mediated protection. IPC and PreC 
protocols have both been demonstrated to elicit HIF1α 
stabilization and transactivational activity – an effect that 
was shown in one study to be specifically PHD2 (and not 
PHD1 or 3) mediated.55 Evidence from a heart model of 
IPC in mice also demonstrated that HIF1α+/− mice have 
reduced IPC-mediated protection from I/R.53 Indeed, fur-
ther evidence in a renal ischemic model showed that the 
inhibition of PHDs and stabilization of HIF1α and 2α was 
sufficient to produce a PreC phenotype.54,64 However, the 
rapidity of induction of the early IPC phase is most likely 
quicker than a HIF-mediated transcriptional response can 
be observed. Therefore, it is possible that the upstream 
oxygen sensors that control HIFs – the PHDs – can induce 
this biphasic response through direct hydroxylation of 
as-yet unknown targets. There is also strong evidence to 
suggest that PHD1 inhibition, which is observed down-
stream of dimethyloxalylglycine (DMOG) treatment, can 
produce a strong protective effect in a number of organ 
systems, which is HIF1α-independent (although it may 
be HIF2α-dependent).10,65 However, considering that PHDs 
themselves can be directly inactivated by increased cellular 
ROS levels, as would occur with repeated I/R cycles, both 
IPC and PostC protocols appear ideal to inactivate these 
enzymes, thereby altering their capacity to hydroxylate 
target substrates. It is possible, therefore, that the PHDs 
themselves may play an important role in protection from 
I/R injury through the loss of hydroxylation of as-yet 
unknown substrates to directly and acutely alter cell sig-
naling. The late phase of IPC, although also downstream 
of PHD signaling, has a profile that is consistent with 
HIF-mediated protection. Although hypoxia-mediated gene 
transcription downstream of HIF can be observed within 
24 hours, full stabilization of this transcriptome can take 
up to 48 hours, which is very similar to the profile of the 
late IPC response.66
Interestingly, it appears that HIF1 activation may be key in 
the remote IPC scenario, where HIF1-mediated  upregulation 
of interleukin-10 as well as stromal cell-derived factor 1 have 
both been shown as capable of inducing remote IPC in the 
heart.67–69 Interleukin-10 provides protection from I/R injury 
through activation of AKT signaling during oxygen–glucose 
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deprivation of cortical neurons, suggesting that this mecha-
nism may be pertinent in a number of different tissues.
The concept of ischemic PostC has received much atten-
tion recently due to the potential for ameliorating ischemic 
damage in patients received into emergency departments 
after an ischemic incident. PostC is carried out using a 
series of short I/R cycles immediately upon reperfusion 
after the original ischemic event.61 A large number of sig-
naling pathways have been proposed as being involved in 
this process, including adenosine receptor signaling, altera-
tions in Ca2+ dynamics, and inhibition of the mitochondrial 
permeability transition pore.70–72 Two recent papers reported 
a role for HIF1α in the PostC protection phenomenon.57,73 
In the first, which investigated PostC of the myocardium, 
PostC was elicited through DMOG-mediated inhibition 
of the PHDs, thereby stabilizing HIF1α (and presum-
ably HIF2α) expression.73 In the second, a mechanism for 
sevoflurane-mediated protection from cerebral ischemia 
was investigated.57 The authors found a phosphatidylinositol 
3-kinase (PI-3K)-dependent effect of sevoflurane on HIF1α 
expression, which resulted in increased heme oxygenase 
1 mRNA, a HIF1 target gene. However, the data in these 
papers are also consistent with a HIF1α-independent mecha-
nism that could be through PHD signaling or other PI-3K 
targets. Indeed, PI-3K activation has many protective effects 
on cell viability independently of HIF-1, including through 
the phosphorylation of the proapoptotic protein BAD and the 
enzyme glycogen synthase kinase 3β. It is worth noting that 
the demonstration of sevoflurane-mediated protection by Ye 
et al is part of a growing body of evidence that suggests that 
the HIF signaling axis is a potential mechanism by which 
volatile anesthetics can protect from I/R injury.57,74,75 Much 
more investigation into this area is required in order for 
efficacious clinically relevant therapeutics to be developed 
to be used as PostC agents.
Interplay between adenosine  
signaling and HIFs
Signaling by the metabolite adenosine has long been 
linked to protection from ischemia in the heart, brain, and 
kidney.76–78 Extracellular adenosine is observed as a result 
of cellular damage, release of adenosine from intracellular 
sources, or through the breakdown of extracellular adenosine 
monophosphate (AMP) by 5′-nucleotidases. The increase in 
adenosine levels observed during ischemia in the myocar-
dium are thought to be due to the relative increase in AMP 
concentrations due to the action of adenylate kinase on ade-
nosine diphosphate, producing ATP and AMP.76  Adenosine 
is recognized by plasma membrane-spanning adenosine 
receptors A1, 2A, 2B, and 3 (encoded by ADORA1, 2A, 2B, 
and 3 genes), all of which are G protein-coupled receptors.79 
Types A1 and A3 are G
o/I
 linked, meaning that their activation 
leads to a reduction in adenylyl cyclase activity (and therefore 
cAMP levels) and increased phospholipase C (PLC) activity. 
PLC action on phosphoinositol-containing lipids produces 
inositol phosphates and diacylglycerol, both of which sig-
nal to downstream effector pathways, which includes the 
activation of protein kinase C (PKC). Conversely, A2A and 
B subtypes are coupled to stimulatory G proteins and result 
in increased cAMP levels and protein kinase A activation.79 
Both subtypes are able to activate MAPK signaling. Adenos-
ine signaling through its receptors has been strongly linked 
with modification of myocardial function and survival,76 as 
well as modulation of I/R injury in a different organs.80–84 It 
was initially shown that adenosine infusion alone or as part 
of a cardioplegic solution could be used to increase ATP 
levels during and after short ischemic episodes.85 However, 
adenosine was also shown to play a role in myocardial PreC, 
as treatment with either adenosine or an A1 agonist were 
shown to recapitulate a bona fide IPC stimulus, while an 
adenosine-receptor antagonist reversed the effect of con-
ventional IPC.86,87
It is likely that some of the protection from I/R injury 
through the action of HIFs is mediated through the adenosine-
mediated signaling cascade. HIF1 has been shown to increase 
the expression of the extracellular 5′-nucleotidase CD73 
during intestinal ischemia,56 which would be predicted to 
increase extracellular adenosine concentrations. The authors 
also showed that a DMOG induced an increase in the A2B 
receptor that was abolished in HIF1α−/− mice, suggesting that 
HIF1- dependent protection may be through activation of this 
receptor  (Figure 1). HIF1-dependent induction of A2B has 
also been observed in vascular endothelial cells, where it was 
shown to play a role in hypoxia-induced tubule formation as 
well as barrier protection.88
The other stimulatory G protein-linked adenosine 
 receptor, A2A, has been proposed to modulate HIF1 activity. 
Activation of this receptor in macrophages has been shown 
to increase HIF1α expression and HRE binding in normoxic 
conditions.89 Using inhibitor studies, the authors suggested 
that this stabilization was through AKT and PKCδ activation 
downstream of the A2A receptor. Both these kinases have 
been previously shown to stabilize HIF1α independently 
of oxygen tension; AKT activation is known to result in 
enhanced HIF1α expression through increased translation90 
and PKCδ activation (which could also be downstream of 
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AKT activation) was shown to increase HIF1 binding to 
HREs by an as-yet undescribed mechanism.91 It is possible 
that the regulation of HIF1α by PKCδ could involve phos-
phorylation of the same site as MAPKs, which is known to 
enhance heterodimer formation.30
Interestingly, it has been shown that ADORA2A is a HIF2 
target gene in pulmonary endothelial cells.92 Endothelial 
cells from different sources have been shown to express dif-
ferent levels of the A2A and A2B receptors,92–94 and it has 
been reported that the relative expression of each changes 
upon induction of hypoxia.94 However, signaling through 
A2B and A2A receptors have both been shown to induce 
angiogenesis.92,94 It is also important to note that A2A recep-
tor signaling during ischemia is not always protective; data 
from cerebral ischemic models suggest that blockade of 
A2A receptors protects against associated damage in adult 
rodents.84,95 The effect of this on the ischemic stabilization 
of HIF was not established. Finally, the A3 receptor has also 
been shown to synergize with hypoxia to induce further 
stabilization of HIF1α.96
It is therefore clear that there is a reciprocal relation-
ship between the HIFs and adenosine receptors that varies 
with the expression of both the adenosine receptors and 
HIFα subunits. In the majority of cases, it appears that this 
 signaling axis is protective, but with tissue specific outcomes; 
for example, signaling elicits an angiogenic response in 
endothelial cells whereas, in the myocardium, it appears to 
be prosurvival.
The role of HIFs in the link between 
circadian rhythm and I/R injury
There has been recent interest in the observation that inci-
dence of cardiovascular events, including myocardial infarc-
tions and stroke, varies with the natural circadian rhythm.97 
Interestingly, the circadian rhythm proteins, and most strik-
ingly Per2, were recently identified as altered in the hearts of 
mice deficient for the A2B receptor (ADORA2B−/−).98 These 
mice not only lost the circadian control of Per2, but also lost 
an IPC-induced increase in Per2 expression. Previous stud-
ies have demonstrated that A2B-receptor activation results 
in MAPK activity, which has been demonstrated to regulate 
Per2.99,100 As the mice also lost the ischemic induction of 
glycolytic enzymes and lactate production in Per2−/− mice, 
the authors investigated the ischemic stabilization of HIF1α 
and found that it was abolished.98 These data introduce a 
novel and exciting link between adenosine signaling, control 
of circadian rhythms, and the cellular hypoxic response. 
 Interestingly, there are further links between hypoxia and the 
control of circadian rhythm that may also play a role in I/R 
injury as DEC1 (also known as SHARP1 and Stra13), which 
has been shown to play a role in the regulation of the molecu-
lar clock, is strongly induced by hypoxia in a  HIF-dependent 
mechanism.101,102 However, the role of DEC1 in I/R injury 
has not yet been explored.
Summary – the potential  
for therapeutic targeting  
of the HIF axis
Evidence from a number of tissues and in vitro studies sug-
gests that activation of the HIF axis can protect from I/R 
injury. Therapeutic approaches that target this system, whether 
directly or indirectly, are likely to have beneficial effects on 
patient outcomes. Indeed, a number of studies described above 
support this, and used iron chelators or direct competitive 
inhibitors of the PHD enzymes to stabilize HIF in models of 
stroke and renal and myocardial infarction.55,103–105 It is not 
surprising that there are PHD-inhibiting compounds in both 
preclinical testing and clinical trials for use in acute ischemia. 
Interestingly, the use of iron chelators in neurological diseases 
such as stroke actually predates the discovery of HIFs and 
PHDs, and were used for their ability to preserve cellular 
metabolism (reviewed in  Karuppagounder et al106). Therefore, 
it would not be unexpected if targets for iron chelators other 
than the PHDs and HIFs were found that help preserve tissue 
viability during I/R. Finally, therapies that indirectly target 
the HIF axis are also likely to aid tissue recovery as part of 
a multifactorial approach. Activators of AKT or MAPK sig-
naling, such as the use of insulin during surgery, as well as 
adenosine receptor agonists could be used in combination to 
increase HIF activity before or during ischemia.
However, we need to understand more about the role of 
HIFs in I/R injury, in particular in two areas. First, studies 
are required that dissociate the role of PHD inhibition from 
HIF activation in I/R injury as it is not yet clear whether 
HIF is only one (albeit a central) part of the protective 
effects of PHD inhibition. Second, we need to understand 
the temporal aspects of modulating this system. Direct 
effects of PHD inhibition may well be very rapid as their 
effect is posttranslational, whereas those responses down-
stream of HIFs can take much longer – even hours – to 
manifest themselves. It is possible that PHD inhibition can 
acutely protect tissues, while HIF activation is required 
post-reperfusion.
Regardless, it is clear that this oxygen-sensing system is 
central to the protection of tissues from I/R injury, and further 
work to elucidate the signaling mechanisms surrounding this 
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phenomenon is likely to lead to better options for therapeutic 
interventions to improve clinical outcomes.
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